Loading
A phase 1/2 trial of Temozolomide in advanced solid tumours, run by Novelwise Pharmaceutical Corporation, now recruiting.
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT06012695 by Novelwise Pharmaceutical Corporation, with 79 participants planned, started 2023-08-11 and due to reach its primary completion in 2028-05-30. Interventions recorded: NBM-BMX Capsule, Temozolomide and Standard radiotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/